Bright Minds Biosciences (NASDAQ:DRUG) Trading Down 5.2% – What’s Next?

Posted by Geri Gentry on Sep 3rd, 2026

Bright Minds Biosciences Inc. (NASDAQ:DRUG – Get Free Report)’s stock price fell 5.2% on Thursday . The company traded as low as $67.84 and last traded at $67.4350. Approximately 65,596 shares traded hands during mid-day trading, a decline of 70% from the average daily volume of 220,467 shares. The stock had previously closed at $71.12.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Zacks Research raised Bright Minds Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 21st. Piper Sandler reiterated an “overweight” rating and set a $220.00 price objective (up from $190.00) on shares of Bright Minds Biosciences in a research note on Wednesday, May 20th. Wall Street Zen raised shares of Bright Minds Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, August 22nd. Oppenheimer lowered shares of Bright Minds Biosciences to a “market perform” rating in a research note on Thursday, August 20th. Finally, Benchmark reiterated a “buy” rating on shares of Bright Minds Biosciences in a research note on Thursday, August 20th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $143.83.

View Our Latest Stock Analysis on Bright Minds Biosciences

Bright Minds Biosciences Stock Down 5.2%

The company has a market capitalization of $656.28 million, a P/E ratio of -32.42 and a beta of -5.35. The business has a 50 day simple moving average of $74.43 and a 200-day simple moving average of $76.99.

Bright Minds Biosciences (NASDAQ:DRUG – Get Free Report) last announced its quarterly earnings results on Monday, August 17th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($1.22) by $1.05. Equities analysts forecast that Bright Minds Biosciences Inc. will post -2.93 EPS for the current fiscal year.

Hedge Funds Weigh In On Bright Minds Biosciences

Several large investors have recently made changes to their positions in the business. Orbimed Advisors LLC acquired a new position in shares of Bright Minds Biosciences during the 1st quarter worth $2,919,000. Janus Henderson Group PLC lifted its stake in shares of Bright Minds Biosciences by 11.1% in the 1st quarter. Janus Henderson Group PLC now owns 1,284,324 shares of the company’s stock valued at $93,518,000 after purchasing an additional 128,329 shares during the last quarter. Vivo Capital LLC boosted its holdings in Bright Minds Biosciences by 11.1% in the first quarter. Vivo Capital LLC now owns 557,172 shares of the company’s stock worth $40,657,000 after purchasing an additional 55,555 shares in the last quarter. ADAR1 Capital Management LLC boosted its holdings in Bright Minds Biosciences by 868.6% in the first quarter. ADAR1 Capital Management LLC now owns 33,900 shares of the company’s stock worth $2,474,000 after purchasing an additional 30,400 shares in the last quarter. Finally, Walleye Capital LLC increased its position in Bright Minds Biosciences by 108.0% during the first quarter. Walleye Capital LLC now owns 53,706 shares of the company’s stock worth $3,919,000 after buying an additional 27,880 shares during the last quarter. Institutional investors own 40.52% of the company’s stock.

About Bright Minds Biosciences

(Get Free Report)

Bright Minds Biosciences Inc, trading on the NASDAQ under the symbol DRUG, is a clinical-stage biotechnology company focused on developing novel small-molecule therapeutics for mental health and neurodegenerative disorders. The company’s research leverages proprietary chemistry platforms to create serotonin-modulating and neuroprotective compounds derived from psychedelic-inspired structures. Bright Minds aims to address unmet needs in conditions such as major depressive disorder, post-traumatic stress disorder and Alzheimer’s disease through orally administered treatments.

The company’s lead candidate, BMB-101, is an oral 5-HT2A receptor-modulating compound in clinical development for mood and anxiety disorders.